Justin Ferdinandus

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

Justin Ferdinandus

Aug 1, 2024, 03:07 | Insight

PET-adapted BrECADD versus escBEACOPP in Hodgkin Lymphoma

Graham Collins, Associate Professor, Haematology and lymphoma specialist at Oxford Cancer and Haematology centre, shared…

Jul 16, 2024, 07:54 | Blog

Michael Hallek: PET-guided BrECADD versus eBEACOPP in Hodgkin lymphoma

Michael Hallek, Director of Clinic I for Internal Medicine and Associated Principle Investigator at the University…

Jul 6, 2024, 09:58 | Insight

Justin Ferdinandus: BrECADD is better tolerated than eBEACOPP for patients with advanced Hodgkin Lymphoma

Justin Ferdinandus, Resident Physician at University Hospital Cologne, shared on X: “HD21 results now finally published…

All: 3 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023